InMed Pharmaceuticals (INM) Stock Soars 32% on R&D Updates

  • InMed Pharmaceuticals (INM) stock is climbing on changes to its business.
  • That includes InMed focusing more on its core research and development (R&D) efforts.
  • The company is also winding down its commercial health and wellness business.
INM Stock. Young green medicinal marijuana plant in a pot after a rain fall shallow depth of field with focus on leaf; cannabis stocks

Source: gvictoria / Shutterstock.com

InMed Pharmaceuticals (NASDAQ:INM) stock is rocketing higher on Friday after the company revealed research and development (R&D) updates.

According to the cannabis company, InMed is reevaluating its business to better focus on core pharmaceutical efforts. That includes plans to enroll patients in a Phase 2 clinical trial by the end of 2022.

This clinical trial has InMed seeking to treat epidermolysis bullosa (EB). The company is also working to develop a “preclinical drug candidate in ocular disease” as well as further research into proprietary cannabinoid analogs.

INM is Changing Its Commerical Business

One major change that’s coming is to InMed Pharmaceuticals’ commercial business. The company has been targeting the health and wellness market following its purchase of BayMedica last year. However, results haven’t been as expected.

InMed Pharmaceuticals notes that several factors are weighing on its efforts in the health and wellness market. As a result, the company is winding down this part of its business. This will have it reporting a non-cash impairment charge in its upcoming earnings report.

InMed Pharmaceuticals CEO Eric Adams said the following in a news release:

“Our goal is to invest where we see the greatest potential for a return and, in doing so, we must take into account evolving market dynamics. As a result, we have made the decision to focus on our core business in the pharmaceutical drug development area and reduce our financial exposure in the H&W sector.”

Today’s news has INM stock seeing heavy trading. That has some 1 million shares on the move as of this writing. The company’s daily average trading volume is about 46,000 shares.

INM stock is up nearly 32% as of Friday morning.

There’s more stock market news for investors to dive into below!

InvestorPlace is home to all of the hottest stock news traders need to know about today! That includes what’s going on with CF Acquisition VI (NASDAQ:CFVI) and DocuSign (NASDAQ:DOCU) stock, as well as this morning’s biggest pre-market stock movers. You can get all of this news from the following links!

More Friday Stock Market News


Article printed from InvestorPlace Media, https://investorplace.com/2022/09/inmed-pharmaceuticals-inm-stock-soars-32-on-rd-updates/.

©2022 InvestorPlace Media, LLC